Lanean...
Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment
PURPOSE: In the clinical setting, raloxifene, a second-generation selective estrogen receptor modulator, is administered orally; however, the bioavailability (BA) is only 2% because of its poor solubility in aqueous fluids and its extensive first-pass metabolism. Therefore, it is expected that the d...
Gorde:
| Argitaratua izan da: | Int J Nanomedicine |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6135211/ https://ncbi.nlm.nih.gov/pubmed/30233182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S173216 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|